Chimeric antigen receptor T (CAR-T) cell therapy demonstrates remarkable efficacy in cancer treatment but faces significant challenges due to adverse effects like cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and on-target off-tumor toxicities (OTOT). This review explores the use of biomaterials to mitigate these side effects. It delves into the mechanisms of CRS, ICANS, and OTOT, and presents innovative strategies using biomaterials to enhance the safety and efficacy of CAR-T cell therapy, transcending conventional treatment paradigms.
Publisher
Pharmaceutics
Published On
Jan 22, 2024
Authors
Zhaozhao Chen, Yu Hu, Heng Mei
Tags
CAR-T cell therapy
biomaterials
cytokine release syndrome
neurotoxicity
cancer treatment
therapy efficacy
on-target off-tumor toxicities
Related Publications
Explore these studies to deepen your understanding of the subject.
